A5005928906- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Pharmacological Effects and Toxicity Studies
- Reproductive Health and Contraception
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Pregnancy and Medication Impact
- Hepatitis C virus research
- HIV, Drug Use, Sexual Risk
- Antibiotic Use and Resistance
- Drug Transport and Resistance Mechanisms
- Global Maternal and Child Health
- Sexual function and dysfunction studies
- LGBTQ Health, Identity, and Policy
- Antibiotic Resistance in Bacteria
- Hepatitis B Virus Studies
- Systemic Lupus Erythematosus Research
- Pharmaceutical Practices and Patient Outcomes
- Blood groups and transfusion
- Sexuality, Behavior, and Technology
- Biochemical and Molecular Research
- Antibiotics Pharmacokinetics and Efficacy
- Adolescent Sexual and Reproductive Health
- Sex and Gender in Healthcare
University of Nebraska Medical Center
2016-2025
Nebraska Medical Center
2014-2024
University of Nebraska at Omaha
2020-2023
Northwestern University
2002-2014
Center for Global Health
2011-2014
IS practice
2010-2014
Northwestern Memorial Hospital
2000-2013
University of Missouri
2011
University of Rochester
2011
Johns Hopkins University
2011
Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or treat during pregnancy. Physiological changes in pregnancy alter pharmacokinetics some medications; thus, our aim was compare pharmacokinetic parameters ledipasvir 90 mg plus sofosbuvir 400 with non-pregnant women.This an open-label, phase 1 study genotype and their infants. A reference group who had participated studies...
Journal Article Pharmacist participation in medical rounds reduces medication errors Get access Kimberly K. Scarsi, Pharm.D., Pharm.D. Clinical Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL Address correspondence to Dr. Scarsi at the Feinberg LC-700, 251 East Huron Street, 60611 (kscarsi@nmh.org). Search for other works by this author on: Oxford Academic Google Scholar Michael A. Fotis, B.S.Pharm., B.S.Pharm. Manager Drug Policy and Staff Development Gary Noskin, M.D....
We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment HIV-associated cognitive impairment.
Background. Levonorgestrel subdermal implants are preferred contraceptives with an expected failure rate of <1% over 5 years. We assessed the effect efavirenz- or nevirapine-based antiretroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics.
Abstract Background Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV acquisition, yet significant barriers exist to its prescription and use. Incorporating pharmacists in PrEP care process may help increase access services. Methods Our pharmacist-led program (P-PrEP) included from a university-based clinic, community pharmacy, 2 community-based clinics. Through collaborative practice agreement, conducted visits with potential candidates...
Objectives: The aim of the study was to compare intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics tenofovir (TFV) its metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat (COBI) FDC containing alafenamide (TAF)/FTC/EVG/COBI. Design: A single-arm, prospective, nonrandomized, cross-over, pharmacokinetic receiving...
Abstract Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use LA ARVs into routine clinical practice requires significant changes to the current framework prevention, treatment, service provision. Given novelty, complexity, interdisciplinary requirements needed safely optimally utilize ARVs, consensus recommendations...
Abstract Background Limited real-world data exist regarding usage of doxycline post-exposure prophylaxis (doxyPEP). We evaluated appropriate doxyPEP prescribing and monitoring following implementation a protocol at the University Nebraska Medical Center (UNMC) Specialty Care Clinic. Methods retrospectively patients receiving between 3/1/2023-2/29/2024. Patients doxycycline for other indications were excluded. The primary outcome was adherence to UNMC protocol. Secondary outcomes included...
Abstract Appropriate, protocol-adherent, doxycycline postexposure prophylaxis prescribing occurred for 70% of prescriptions from our clinic. Most the nonadherent was due to missed sexually transmitted infection screenings (89%). As utilization continues increase, it is necessary ensure appropriate follow-up and monitoring.
This Viewpoint reviews the US legal landscape for regulation of drugs with potential addiction, pharmacology mifepristone and misoprostol, evidence demonstrating their lack dependency, consequences 2024 policy changes in Louisiana state law.
Objectives: The primary objective of this study was to characterize the pharmacokinetics etonogestrel (ENG) released from a contraceptive implant in Ugandan women living with HIV who were receiving efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART), compared ART-naive over 24 weeks. Design: Nonrandomized, parallel-group three arms: ART-naive, NVP, EFV-based ART (N = 20/group). Methods: Sparse pharmacokinetic sampling ENG, EFV performed at screening, entry, and then 1, 4,...
Abstract Background Human immunodeficiency virus (HIV) viral suppression (VS) decreases morbidity, mortality, and transmission risk. Methods The Patient-centered HIV Care Model integrated community-based pharmacists with medical providers required them to share patient clinical information, identify therapy-related problems, develop action plans. Proportions adherent antiretroviral therapy (proportion of days covered [PDC] ≥90%) virally suppressed (HIV RNA &lt;200 copies/mL), before...
Background To date, antiretroviral therapy (ART) guidelines and programs in resource-limited settings (RLS) have focused on 1st- 2nd-line (2 L) therapy. As approach a decade of implementation, policy regarding access to 3rd-line (3 ART is needed. We aimed examine the impact maintaining patients failing 2 L accumulation protease (PR) mutations. Methods Findings From 2004–2011, Harvard/APIN PEPFAR Program provided >100,000 people Nigeria. Genotypic resistance testing was performed subset...